Table 4. Pathway enrichment analysis.
| Pathway ID | Term | Genes | Bonferroni adjusted p-value | FDR | |
|---|---|---|---|---|---|
| A | hsa05200 | Pathways in cancer | E2F3, COL4A1, MAP2K1, MET, CDK6, WNT1, CDC42, CCND1, BCL2, VEGFA, LAMC1, AXIN2, MYC | 1.93E-06 | 3.11E-05 |
| hsa04510 | Focal adhesion | CDC42, CCND1, COL4A1, MAP2K1, BCL2, MET, VEGFA, COL3A1, COL1A2, LAMC1, COL1A1 | 2.20E-06 | 3.54E-05 | |
| hsa05222 | Small cell lung cancer | E2F3, CCND1, COL4A1, BCL2, CDK6, LAMC1, MYC | 2.40E-04 | 3.90E-03 | |
| hsa05212 | Pancreatic cancer | CDC42, E2F3, CCND1, MAP2K1, VEGFA, CDK6 | 2.30E-04 | 3.20E-04 | |
| B | hsa05216 | Thyroid cancer | CCND1, TP53, LEF1, MYC, TCF7L1, CTNNB1 | 1.28E-04 | 1.91E-03 |
| hsa04310 | Wnt signaling pathway | WNT1, CCND1, CSNK1E, MMP7, TP53, LEF1, MYC, TCF7L1, CTNNB1 | 7.95E-04 | 1.19E-02 | |
| hsa05213 | Endometrial cancer | CCND1, TP53, LEF1, MYC, TCF7L1, CTNNB1 | 2.46E-03 | 3.69E-02 |
FDR, false discovery rate; A, pathway enrichment analysis of the verified target genes of miRNAs; B, pathway enrichment analysis of genes in the miRNAs-transcription factors-target genes network.